Biolex, Inc., a biotechnology discovery company, has signed a research collaboration agreement with Bayer Corporation to explore the feasibility of producing human plasminogen and “an undisclosed human therapeutic protein” using Biolex’ Lemna System. Terms of the deal were not disclosed.

The Lemna System, based on the aquatic plant, combines the natural characteristics of Lemna with other protein recovery methods, according to information published on the privately held, venture-backed firm.

Lemna’s advantages over other forms of bio-testing because the plant doubles its biomass every 36 hours, has a high protein content and is inexpensive to grow, according to Biolex.

More information about Biolex’ Lemna System is available on the company’s Web site.